Earnings Sentiment

Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.

Please consider a small donation if you think this website provides you with relevant information  

    

Sentiment Distribution

   

Earnings Call Transcript Word Cloud

     

Bullish Statements during Earnings call

Statement
So our performance in the face of that headwind was strong as well
The business fundamentals for the company were solid in the quarter with broad-based volume growth on a same facility basis across our footprint and various service lines
These results reflected continued strong demand for our services and healthy operating margins on a same facility basis
I think the revenue yield from acuity, payer mix, and pricing is positive
So across geography and across service lines, really solid performance
We're positioned very well, and our same facility operations is going pretty well
We have proven standards and processes over time that we think create a really good experience and a positive outcome for our patients
And the early results of our program are really positive
Inpatient volumes were supported by continued strong acuity and a favorable payer mix with same facility commercial admissions growing an impressive 7%
Good demand in the market
But as I said, and Sam mentioned in his comments, we're pleased with the core fundamentals that we're seeing
We are encouraged by our ER revitalization program and the results it is producing for our patients
We've made, I think, several comments on the core business trends we're seeing with really strong volume, reasonable pricing, the core operating expenses of the company are doing well in labor market supplies
We believe again that our core business, our hospital-centric core business is performing well
I mean, we see a lot of volume strength
Our throughput times with respect to discharging our patients has improved, as well as those who get admitted, we’re able to get them onto the floors more efficiently than we were before
These positive results help reduce contract labor costs 12.5% as compared to the third quarter last year and 11% sequentially
So I think as a team, we have confidence we can continue to operate the company at reasonably strong efficiency levels
So all of that to say is its yielded volume growth, it's yielded patient throughput improvement, and most importantly, it's yielded patient satisfaction increases that we are encouraged by and we will continue to hopefully achieve
I'm proud of our people for what they do every day to deliver on our purpose
So we're reasonably optimistic here that the overall top line metrics that you are seeing have durability
And so from our standpoint, economies remain strong across our portfolio, and we believe that supports some of the payer mix trends that we've seen
This focused approach, which benefits all stakeholders, enhances our ability to execute clinically, strategically and financially
Our overall competitive positioning, we believe continues to be strong
It’s our belief that demand for healthcare remains strong and will remain strong into the future
And so I'm confident, as I've said, that we have the mindset and the wherewithal to work through these and get us to a reasonable solution
And when you consider the $145 million payer settlement we recorded in the first quarter of this year, as we take all of that into account, we are pleased with the growth rate we've been able to achieve
And so, fortunately, our balance sheet remains strong as Bill alluded to, and our ability to invest in our agenda to maintain our positioning and execute on our agenda remains strong
But we're seeing positive signs with respect to turnover, with respect to hiring, and even the number of new students who are populating our Galen College of Nursing programs is very encouraging, suggesting that there's a sufficient pipeline of new nurses who want to be educated and go into the workforce
When you look at the mix of business, again, as I said earlier, we had very broad-based service line performance that was solid
       

Bearish Statements during earnings call

Statement
This result was not what we were expecting, as we are experiencing revenue shortfalls compared to what we originally modeled
The Valesco operating results had a negative impact on adjusted EBITDA margins of approximately 80 basis points in the quarter and 40 basis points on a year-to-date basis
Because of this issue primarily, we have lowered the top side of our earnings guidance for the year to reflect the effects of these losses
As Sam mentioned in his comments, the Valesco joint venture had a negative impact of approximately $100 million on the company's adjusted EBITDA in the quarter as well on a year-to-date basis
So that means the revenue dropped sequentially by like $60 million
So again, I think we'll see slowing growth
Our obstetrics volumes, mainly births were down slightly, pediatric was down slightly, and our behavioral was down because we made some capacity adjustments, and not because demand is shrinking in behavioral
Unfortunately, our results were unfavorably impacted by our Valesco hospital-based physician venture
We view the primary issue as revenue shortfalls, and that's what we're working through
I mean as I said, our rate of growth in the third quarter slowed from the rate of growth from the second quarter, although we continue to see subsidy request and we've got efforts to mitigate those
We actually had a calendar headwind in the quarter with respect to surgical days and cardiology procedure days, where we had one less surgical day in the quarter than we did last year
That actually created a little bit of a headwind in the quarter and throughout the year for us
Isolate the margin, really that other operating line is where you see we've lost some margin for over the years [ph] reported quarter
So most of this lands on the Valesco challenge with respect to the revenue and the earnings associated with that venture
Unfortunately, we are dealing with the Valesco integrations and we'll overcome that
We do believe the rate of growth is too slow going forward compared to what we've seen this year
that were less than we expected
I know though there's been a lot of concern about GLP-1 and so forth
And I just have to put -- it's $50 million a quarter, and we have confidence that we've dealt with similar issues in the past, and we'll work through that, but it's primarily a revenue challenge that we'll get through
Excluding Florida DPP from both quarters, EBITDA margin appears to have declined by about 180 basis points year-over-year, suggesting close to $300 million total headwind
   

Please consider a small donation if you think this website provides you with relevant information